Your browser doesn't support javascript.
loading
Analysis of real-world data on growth hormone therapy adherence using a connected injection device.
Koledova, Ekaterina; Tornincasa, Vincenzo; van Dommelen, Paula.
Afiliação
  • Koledova E; Endocrinology Global Medical, Safety and CMO, Merck KGaA, 64293, Darmstadt, Germany. ekaterina.koledova@merckgroup.com.
  • Tornincasa V; Merck Connected Health and Devices, Ares Trading S.A., an affiliate of Merck KGaA, 1262, Eysins, Switzerland.
  • van Dommelen P; The Netherlands Organization for Applied Scientific Research TNO, Leiden, The Netherlands.
BMC Med Inform Decis Mak ; 20(1): 176, 2020 07 29.
Article em En | MEDLINE | ID: mdl-32727461
ABSTRACT

BACKGROUND:

Poor adherence to long-term recombinant human growth hormone (r-hGH) treatment can lead to suboptimal clinical outcomes; consequently, supporting and monitoring adherence is a crucial part of patient management. We assessed adherence to r-hGH treatment in children with growth disorders over 48 months using a connected monitoring device (easypod™), which automatically transmits adherence data via an online portal (easypod™ connect); both sit within an adherence decision support system (ADSS). We also investigated the effect of age and sex on adherence.

METHODS:

Data from children transmitting over 10 injections between January 2007 and February 2019 were analyzed. Adherence (mg injected/mg prescribed) was categorized as high (≥85%), intermediate (> 56-84%) or low (≤56%) and assessed at seven time points from the start of treatment up to 48 months. Adherence was investigated over time and stratified by puberty status and sex. Mean transmission rate in each adherence category (total number of transmissions/total number of children) at each time point was calculated as a proxy measure of engagement in disease and treatment management. Descriptive analyses were performed.

RESULTS:

Longitudinal records were available for 13,553 children. Overall, 71% (n = 9578) had high adherence, 22% (n = 2989) intermediate and 7% (n = 986) low. The proportion of children with high adherence decreased over time from 87% (n = 12,964) to 65% (n = 957) and was higher in pre-pubertal than pubertal children (girls 80% [n = 1270] vs 70% [n = 4496]; boys 79% [n = 2573] vs 65% [n = 5214]). Children with high adherence had a higher mean number of transmissions (12.5 [SD 24.9]) than children with intermediate (7.2 [SD 15.3]) or low (3.5 [SD 5.7]) adherence.

CONCLUSIONS:

High adherence was seen in patients administering r-hGH using the connected device. Children with high adherence were most likely to regularly transmit data. Pubertal children showed lower adherence. We show the potential to develop an ADSS to analyze trends in real-world adherence data. This may prove useful to direct interventions to improve adherence while the ability to readily share data with healthcare professionals may itself improve adherence.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cooperação do Paciente Tipo de estudo: Prognostic_studies Limite: Adolescent / Child / Female / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cooperação do Paciente Tipo de estudo: Prognostic_studies Limite: Adolescent / Child / Female / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article